Target volume coverage in clinically designed radiotherapy plan of post-mastectomy adjuvant radiotherapy of breast cancer patients in comparison with radiation therapy oncology group-based contoured plan: A dosimetric study

被引:1
作者
Azam, Mohammad [1 ]
Agrawal, Animesh [2 ]
Sahni, Kamal [3 ]
Rastogi, Madhup [3 ]
Rathi, Arun Kumar [1 ]
Farzana, S. [4 ]
机构
[1] Maulana Azad Med Coll, Dept Radiat Oncol, New Delhi 110002, India
[2] Gujarat Canc Res Inst, Dept Med Oncol, Ahmadabad, Gujarat, India
[3] Dr RMLIMS, Dept Radiat Oncol, Lucknow, Uttar Pradesh, India
[4] Chirayu Med Coll, Dept Radiat Oncol, Bhopal, Madhya Pradesh, India
关键词
Breast cancer; modified radical mastectomy; radiation dosimetry; radiation therapy oncology group contouring guidelines; three-dimensional conformal radiotherapy; POSTOPERATIVE RADIOTHERAPY; PREMENOPAUSAL WOMEN;
D O I
10.4103/jcrt.jcrt_1212_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Conventional field radiotherapy based on anatomical landmarks has been the traditional treatment for breast cancer. Having proven efficacy, it is still the current standard of treatment. The Radiation Therapy Oncology Group (RTOG) has published guidelines for contouring target volumes in postmastectomy patients. The impact of this guideline in the current clinical practice is less known; hence, we have analyzed dose-volume histograms (DVHs) for these plans and compared them with the proposed treatment plans to treat RTOG-defined targets. Subjects and Methods: RTOG consensus definitions were used to contour the target volumes in 20 previously treated postmastectomy patients. The prescription was 42.4 Gy in 16 fractions. DVHs were generated from clinically designed plans that had actually been delivered to each patient. For comparing dose to target volumes, new plans were generated with the goal of covering 95% of volume to 90% of prescribed dose. Results: In RTOG contoured Group, coverage improved for the supraclavicular (V90 = 83 vs. 94.9%, P < 0.05) and chest wall (V90 = 89.8 vs. 95.2%, P < 0.05). Axillary nodal coverage improved for Level-1(V90 = 80.35 vs. 96.40%, P < 0.05), Level-II (V90 = 85.93 vs. 97.09%, P < 0.05) and Level III (V90 = 86.67 vs. 98.6%, P < 0.05). The dose to the ipsilateral lung is increased (V20 = 23.87 vs. 28.73%, P < 0.05). Low dose to heart is increased in left-sided cases (V5 = 14.52 vs. 16.72%, P < 0.05) while same in right-sided cases. Conclusions: The study shows that radiotherapy using the RTOG consensus guidelines improves coverage to target volumes with a nonsignificant increase in normal organ dose compared to that based on anatomical landmarks.
引用
收藏
页码:159 / 164
页数:6
相关论文
共 12 条
[1]  
[Anonymous], Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions
[2]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[3]   Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radiation therapy [J].
Fontanilla, Hiral P. ;
Woodward, Wendy A. ;
Lindberg, Mary E. ;
Kanke, James E. ;
Arora, Gurpreet ;
Durbin, Rosalind R. ;
Yu, Tse-Kuan ;
Zhang, Lifei ;
Sharp, Hadley J. ;
Strom, Eric A. ;
Salehpour, Mohammad ;
White, Julia ;
Buchholz, Thomas A. ;
Dong, Lei .
PRACTICAL RADIATION ONCOLOGY, 2012, 2 (03) :201-209
[4]  
ICMR-NICPR, 2018, Breast Cancer, P1
[5]   Skin Toxicity in Early Breast Cancer Patients Treated with Field-In-Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy: Results of a Phase III Randomised Controlled Trial [J].
Joseph, K. ;
Vos, L. J. ;
Gabos, Z. ;
Pervez, N. ;
Chafe, S. ;
Tankel, K. ;
Warkentin, H. ;
Ghosh, S. ;
Amanie, J. ;
Powell, K. ;
Polkosnik, L-A ;
Horsman, S. ;
MacKenzie, M. ;
Sabri, S. ;
Parliament, M. B. ;
Mackey, J. ;
Abdulkarim, B. .
CLINICAL ONCOLOGY, 2021, 33 (01) :30-39
[6]   Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials [J].
McGale, P. ;
Taylor, C. ;
Correa, C. ;
Cutter, D. ;
Duane, F. ;
Ewertz, M. ;
Gray, R. ;
Mannu, G. ;
Peto, R. ;
Whelan, T. ;
Wang, Y. ;
Wang, Z. ;
Darby, S. .
LANCET, 2014, 383 (9935) :2127-2135
[7]   Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial [J].
Overgaard, M ;
Jensen, MB ;
Overgaard, J ;
Hansen, PS ;
Rose, C ;
Andersson, M ;
Kamby, C ;
Kjær, M ;
Gadeberg, CC ;
Rasmussen, BB ;
Blichert-Toft, M ;
Mouridsen, HT .
LANCET, 1999, 353 (9165) :1641-1648
[8]   Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy [J].
Overgaard, M ;
Hansen, PS ;
Overgaard, J ;
Rose, C ;
Andersson, M ;
Bach, F ;
Kjaer, M ;
Gadeberg, CC ;
Mouridsen, HT ;
Jensen, MB ;
Zedeler, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :949-955
[9]   Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [J].
Ragaz, J ;
Jackson, SM ;
Le, N ;
Plenderleith, IH ;
Spinelli, JJ ;
Basco, VE ;
Wilson, KS ;
Knowling, MA ;
Coppin, CML ;
Paradis, M ;
Coldman, AJ ;
Olivotto, IA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :956-962
[10]  
Ramseier Julie Y, 2020, Int J Womens Dermatol, V6, P349, DOI 10.1016/j.ijwd.2020.07.015